Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Greta Pessino, Claudia Scotti, Maristella Maggi, Immuno-Hub Consortium
Liver cancer, predominantly hepatocellular carcinoma (HCC), globally ranks sixth in incidence and third in cancer-related deaths. HCC risk factors include non-viral hepatitis, alcohol abuse, environmental exposures, and genetic factors. No specific genetic alterations are unequivocally linked to HCC tumorigenesis. Current standard therapies include surgical options, systemic chemotherapy, and kinase inhibitors, like sorafenib and regorafenib. Immunotherapy, targeting immune checkpoints, represents a promising avenue...
February 23, 2024: Cancers
#22
REVIEW
Anne Jacobsen, Jürgen Siebler, Robert Grützmann, Michael Stürzl, Elisabeth Naschberger
The vasculature is a key player and regulatory component in the multicellular microenvironment of solid tumors and, consequently, a therapeutic target. In colorectal carcinoma (CRC), antiangiogenic treatment was approved almost 20 years ago, but there are still no valid predictors of response. In addition, treatment resistance has become a problem. Vascular heterogeneity and plasticity due to species-, organ-, and milieu-dependent phenotypic and functional differences of blood vascular cells reduced the hope of being able to apply a standard approach of antiangiogenic therapy to all patients...
February 22, 2024: Cancers
#23
JOURNAL ARTICLE
Junfeng Zhu, Like Zhong, Yu Song, Haiying Ding, Wenxiu Xin, Gaoqi Xu, Luo Fang
Regorafenib is a small-molecule tyrosine kinase inhibitor with severe hepatotoxicity. It undergoes metabolism mainly by CYP3A4 to generate active metabolites regorafenib-N-oxide (M2) and N-desmethyl-regorafenib-N-oxide (M5). Wuzhi capsule (WZC) is an herbal preparation derived from Schisandra sphenanthera and is potentially used to prevent regorafenib-induced hepatotoxicity. This study aims to explore the effect of WZC on the pharmacokinetics of regorafenib in rats. An efficient and sensitive liquid chromatography-tandem mass spectrometry method was developed to quantitatively determine regorafenib and its main metabolites in rat plasma...
March 2024: Journal of Separation Science
#24
JOURNAL ARTICLE
Bo Hyun Kim, Hee Chul Park, Tae Hyun Kim, Young-Hwan Koh, Jung Yong Hong, Yuri Cho, Dong Hyun Sinn, Boram Park, Joong-Won Park
BACKGROUND AND AIMS: Nivolumab was the first immune checkpoint inhibitor approved for hepatocellular carcinoma (HCC). External beam radiation therapy (EBRT) is locally effective and may enhance the effectiveness of immunotherapy. This study investigated the efficacy and safety of concurrent nivolumab and EBRT in HCC with macrovascular invasion. METHODS: In this phase II multicenter trial, patients with HCC and macrovascular invasion were concurrently treated with intravenous nivolumab (3 mg/kg every 2 weeks) and EBRT, followed by maintenance nivolumab until progression or unacceptable toxicity...
April 2024: JHEP reports: innovation in hepatology
#25
JOURNAL ARTICLE
Koutaro Ono, Remi Murase, Natsumi Matsumoto, Yutaro Kubota, Hiroo Ishida, Ken-Ichi Fujita
PURPOSE: Treatment with regorafenib, which inhibits vascular endothelial growth factor (VEGF) receptor, frequently results in hand-foot skin reaction (HFSR), requiring treatment discontinuation or dose reduction. In our prospective study of regorafenib on patients with metastatic colorectal cancer, 17% of patients developed grade 3 HFSR. Herein, we retrospectively examined genetic polymorphisms associated with regorafenib-induced severe HFSR. METHODS: To identify associated polymorphisms, exploratory whole-exome sequencing focusing on factors related to VEGF-mediated signaling pathways was first performed in seven patients each, with grade 3 HFSR and without HFSR...
March 8, 2024: Cancer Chemotherapy and Pharmacology
#26
JOURNAL ARTICLE
Yue Wang, Yixuan Du, Hongfei Huang, Yiming Cao, Kemeng Pan, Yueqian Zhou, Jiawei He, Wenbing Yao, Song Chen, Xiangdong Gao
Altered glycosylation profiles have been correlated with potential drug targets in various diseases, including Alzheimer's disease (AD). In this area, the linkage between bisecting N-acetylglucosamine (GlcNAc), a product of N-acetylglucosaminyltransferase III (GnT-III), and AD has been recognized, however, our understanding of the cause and the causative role of this aberrant glycosylation in AD are far from completion. Moreover, the effects and mechanisms of glycosylation-targeting interventions on memory and cognition, and novel targeting strategies are worth further study...
March 6, 2024: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
#27
JOURNAL ARTICLE
Andrew S Poklepovic, Sarah W Gordon, Sejal Kothadia, William P McGuire, Leroy R Thacker, Xiaoyan Deng, Mary Beth Tombes, Ellen Shrader, Daniel Hudson, Dipankar Bandyopadhyay, Alison A Ryan, Maciej Kmieciak, Steven Smith, Paul Dent
The purpose of this study is to establish the recommended phase 2 dose for regorafenib in combination with sildenafil for patients with advanced solid tumors. Secondary outcomes included identification of antitumor effects of regorafenib and sildenafil, toxicity of the combination, determination of PDE5 expression in tumor samples, and the impact of sildenafil on the pharmacokinetics of regorafenib. This study was a phase 1, open-label single-arm dose-escalation trial using a 3 + 3 design. Additional patients were enrolled at the maximum tolerated dose (MTD) until a total of 12 patients were treated at the MTD...
June 1, 2024: Anti-cancer Drugs
#28
Maria Alessandra Bellia, Carmelo Sofia, Maria Adele Marino, Carmelo Mazzeo, Santino Antonio Biondo, Eugenio Cucinotta, Francesco Fleres
Regorafenib is a multikinase inhibitor approved for treatment of patients with metastatic Colo-Rectal Cancer (mCRC) and Gastro-Intestinal Stromal Tumor (GIST) progression after the administration of other tyrosine-kinase inhibitors such as imatinib and sunitinib. Only a handful of severe side effects such as intestinal perforations and fistulas have been described in the literature in patients undergoing multikinase inhibitor treatment. We report a case of a patient with peritoneal mCRC who experienced an intestinal perforation during the administration of Regorafenib and review the literature...
May 2024: Radiology Case Reports
#29
JOURNAL ARTICLE
Yoshitaka Saito, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara
Regorafenib is the first multikinase inhibitor for treating metastatic colorectal cancer (mCRC). Proteinuria is a frequently encountered adverse effect, regardless of prior administration of vascular endothelial growth factor inhibitors. Herein, we aimed to assess the impact of baseline preexisting proteinuria on regorafenib-induced problematic proteinuria during real-world mCRC therapy. Patients with mCRC receiving regorafenib (n = 100) were retrospectively assessed and divided into control and preexisting proteinuria (baseline grade of 1-2) groups...
March 2, 2024: Scientific Reports
#30
JOURNAL ARTICLE
Ahmed A Abdelgalil, Hamad M Alkahtani
Regorafenib is a small molecule tyrosine kinase inhibitor administered orally drug, act by inhibiting the activity of the VEGF receptors. It is used for the treatment of patients with metastatic colorectal cancer (CRC), advanced gastrointestinal stromal tumors, and hepatocellular carcinoma. This comprehensive profile on regorafenib includes an original data as well as data collected from the literature on Profiles of Methods of Drug Synthesis, different Physical Drug Profiles, Drug Analytical methods and Pharmacological profile (ADME)...
2024: Profiles of Drug Substances, Excipients, and related Methodology
#31
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 19, 2024: Medical Letter on Drugs and Therapeutics
#32
JOURNAL ARTICLE
Pilar García-Alfonso, Ruth Vera, Enrique Aranda, Elena Élez, Fernando Rivera
PURPOSE: The optimal drug regimen and sequence are still unknown for patients with metastatic colorectal cancer (mCRC) who are candidates for third-line (3L) or subsequent treatment. The aim of this study is to know the opinion of experts on the most appropriate treatment options for mCRC in 3L and to clarify certain clinical decisions in Spain. METHODS: Using a modified Delphi method, a group of experts discussed the treatment in 3L of patients with mCRC and developed a questionnaire with 21 items divided into 5 sections...
February 27, 2024: Clinical & Translational Oncology
#33
JOURNAL ARTICLE
André L F Azeredo-da-Silva, Victor Hugo F de Jesus, Ion Agirrezabal, Victoria K Brennan, Phuong L Carion, Nathalie Amoury, Bruna M Vetromilla, Bruna S Zanotto, Suki Shergill, Patricia K Ziegelmann
INTRODUCTION: This literature review and exploratory network meta-analysis (NMA) aimed to compare the clinical effectiveness and tolerability of selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) resin microspheres, regorafenib (REG), trifluridine-tipiracil (TFD/TPI), and best supportive care (BSC) in adult patients with chemotherapy-refractory or chemotherapy-intolerant metastatic colorectal cancer (mCRC). METHODS: In light of recently published data, the literature was searched to complement and update a review published in 2018...
February 26, 2024: Advances in Therapy
#34
JOURNAL ARTICLE
Regorafenib modulation of the angiopoietin/TIE2 axis in a mouse model of sepsis-induced lung injury.
Mohammed Hamzah Ibadi, Sahar Majeed, Fadhaa Abdulameer Ghafil, Najah Rayish Hadi
Sepsis, often resulting from an immune response overreaction to microorganisms and their products, can lead to acute lung injury through inflammation mediated by excessive cytokines. This study aimed to investigate the effects of regorafenib on lung injury in mice following the induction of sepsis. We divided mice into four groups (n=6 each): a sham group (undergoing laparotomy without cecal ligation and puncture [CLP]), a CLP group, a vehicle group, and a regorafenib-treated group (30 mg/kg IP, administered one hour before CLP)...
November 2023: Journal of Medicine and Life
#35
REVIEW
Alberto Repici, Alessio Ardizzone, Fabiola De Luca, Lorenzo Colarossi, Angela Prestifilippo, Gabriele Pizzino, Irene Paterniti, Emanuela Esposito, Anna Paola Capra
Brain tumors are a diverse collection of neoplasms affecting the brain with a high prevalence rate in people of all ages around the globe. In this pathological context, glioblastoma, a form of glioma that belongs to the IV-grade astrocytoma group, is the most common and most aggressive form of the primary brain tumors. Indeed, despite the best treatments available including surgery, radiotherapy or a pharmacological approach with Temozolomide, glioblastoma patients' mortality is still high, within a few months of diagnosis...
February 19, 2024: Cells
#36
JOURNAL ARTICLE
Somaieh Hedayat, Luciano Cascione, David Cunningham, Marta Schirripa, Andrea Lampis, Jens C Hahne, Nina Tunariu, Sung Pil Hong, Silvia Marchetti, Khurum Khan, Elisa Fontana, Valentina Angerilli, Mia Delrieux, Daniel Nava Rodrigues, Letizia Procaccio, Sheela Rao, David Watkins, Naureen Starling, Ian Chau, Chiara Braconi, Nicos Fotiadis, Ruwaida Begum, Naomi Guppy, Louise Howell, Melanie Valenti, Scott Cribbes, Bernadett Kolozsvari, Vladimir Kirkin, Sara Lonardi, Michele Ghidini, Rodolfo Passalacqua, Raghad Elghadi, Luca Magnani, David J Pinato, Federica Di Maggio, Filippo Ghelardi, Elisa Sottotetti, Guglielmo Vetere, Paolo Ciraci, Georgios Vlachogiannis, Filippo Pietrantonio, Chiara Cremolini, Alessio Cortellini, Fotios Loupakis, Matteo Fassan, Nicola Valeri
BACKGROUND: The multi-kinase inhibitor regorafenib has demonstrated efficacy in chemo-refractory metastatic colorectal cancer (mCRC) patients. However, lack of predictive biomarkers and concerns over significant toxicities hamper the use of regorafenib in clinical practice. METHODS: Serial liquid biopsies were obtained at baseline and monthly until disease progression in chemo-refractory mCRC patients treated with regorafenib in a phase II clinical trial (PROSPECT-R n=40; NCT03010722) and in a multicentric validation cohort (n=241)...
February 20, 2024: Clinical Cancer Research
#37
MULTICENTER STUDY
Hyung-Don Kim, Seyoung Jung, Ho Yeong Lim, Baek-Yeol Ryoo, Min-Hee Ryu, Samuel Chuah, Hong Jae Chon, Beodeul Kang, Jung Yong Hong, Han Chu Lee, Deok-Bog Moon, Ki-Hun Kim, Tae Won Kim, David Tai, Valerie Chew, Jeong Seok Lee, Richard S Finn, June-Young Koh, Changhoon Yoo
Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma (uHCC) with potential immunomodulatory effects, suggesting that its combination with immune checkpoint inhibitor may have clinically meaningful benefits in patients with uHCC. The multicenter, single-arm, phase 2 RENOBATE trial tested regorafenib-nivolumab as front-line treatment for uHCC. Forty-two patients received nivolumab 480 mg every 4 weeks and regorafenib 80 mg daily (3-weeks-on/1-week-off schedule)...
March 2024: Nature Medicine
#38
JOURNAL ARTICLE
Hiroyuki Arai, Yan Yang, Yasmine Baca, Joshua Millstein, Tadamichi Denda, Fang-Shu Ou, Federico Innocenti, Hiroyuki Takeda, Yohei Kubota, Ayako Doi, Yoshiki Horie, Kumiko Umemoto, Naoki Izawa, Jingyuan Wang, Francesca Battaglin, Priya Jayachandran, Sandra Algaze, Shivani Soni, Wu Zhang, Richard M Goldberg, Michael J Hall, Aaron James Scott, Jimmy J Hwang, Emil Lou, Benjamin A Weinberg, John Marshall, Sanjay Goel, Joanne Xiu, W Michael Korn, Alan P Venook, Yu Sunakawa, Heinz-Josef Lenz
BACKGROUND: CDC37 is a key determinant of client kinase recruitment to the HSP90 chaperoning system. We hypothesized that kinase-specific dependency on CDC37 alters the efficacy of targeted therapies for metastatic colorectal cancer (mCRC). MATERIAL AND METHODS: Two independent mCRC cohorts were analyzed to compare the survival outcomes between CDC37-high and CDC37-low patients (stratified by the median cutoff values): the CALGB/SWOG 80405 trial (226 and 207 patients receiving first-line bevacizumab- and cetuximab-containing chemotherapies, respectively) and Japanese retrospective (50 refractory patients receiving regorafenib) cohorts...
February 10, 2024: European Journal of Cancer
#39
JOURNAL ARTICLE
He-Ming Zhou, Da-Hong Chen, Wen-Jing Diao, Ya-Fei Wu, Ji-Gang Zhang, Lin Zhong, Zhong-Yi Jiang, Xue Zhang, Gao-Lin Liu, Qin Li
Patients with hepatocellular carcinoma (HCC) are vulnerable to drug resistance. Although drug resistance has been taken much attention to HCC therapy, little is known of regorafenib and regorafenib resistance (RR). This study aimed to determine the drug resistance pattern and the role of RhoA in RR. Two regorafenib-resistant cell lines were constructed based on Huh7 and Hep3B cell lines. In vitro and in vivo assays were conducted to study RhoA expression, the activity of Hippo signaling pathway and cancer stem cell (CSC) traits...
February 8, 2024: Experimental Cell Research
#40
JOURNAL ARTICLE
Dae Won Kim, Young-Chul Kim, Bence P Kovari, Maria Martinez, Ruoyu Miao, James Yu, Rutika Mehta, Jonathan Strosberg, Iman Imanirad, Richard D Kim
Previously, we reported the modest but durable anticancer activity of regorafenib/nivolumab in mismatch repair-proficient (pMMR) refractory colorectal cancer in our I/Ib study. Our finding suggests the necessity of biomarkers for better selection of patients. Baseline clinical and pathological characteristics, blood and tumor samples from the patients in the trial were collected and evaluated to discover potential biomarkers. The obtained samples were assessed for immunohistochemistry, ELISA and RNA sequencing...
January 28, 2024: Cancers
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
